EWZ vs IBB
iShares MSCI Brazil ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.59% for EWZ.
- • EWZ pays a higher dividend yield (4.51%).
Side-by-side metrics
| Metric | EWZ | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.59% | 0.44% |
Dividend yield Trailing 12-month yield. | 4.51% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $9.62B | $11.50B |
YTD return | 3.62% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.92 | 0.60 |
P/E ratio | 10.36 | 25.48 |
Last price | $32.42 | $217.75 |
Inception | — | — |
Issuer | iShares | iShares |
EWZ top holdings
| VALE3.SA | Vale SA | 8.65% |
| PETR3.SA | Petroleo Brasileiro SA Petrobras | 8.47% |
| NU | Nu Holdings Ltd Ordinary Shares Class A | 8.47% |
| WEGE3.SA | Weg SA | 3.42% |
| AXIA3.SA | Axia Energia | 2.99% |
| EMBJ3.SA | Embraer SA | 2.99% |
| B3SA3.SA | B3 SA - Brasil Bolsa Balcao | 2.98% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About EWZ
EWZ (iShares MSCI Brazil ETF) is Brazilian large- and mid-cap equities. Managed by iShares, the fund carries $9.6B in assets under management, an expense ratio of 0.59%, a dividend yield of 4.51%. Its largest holding is Vale SA (VALE3.SA), which represents 8.7% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 1.5%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.